260 Results

People

  1. Motzer
    Motzer
  2. Baselga
    Baselga
  3. Seidman
    Seidman
  4. Hudis
    Hudis
  5. Ilson
    Ilson
  6. O'Reilly
    O'Reilly
  7. Zelenetz
    Zelenetz
  8. Aghajanian
    Aghajanian
  9. Bajorin
    Bajorin
  10. Schwartz
    Schwartz

Groups

  1. Department of Medicine (207)
  2. Solid Tumor Oncology Division (174)
  3. Genitourinary Oncology Service (58)
  4. Breast Medicine Service (37)
  5. Hematologic Malignancies, Division of (34)
  6. Gastrointestinal Oncology Service (31)
  7. Survivorship Research (28)
  8. Center for Hematologic Malignancies (27)
  9. Gynecologic Medicine Service (22)
  10. Thoracic Oncology (20)
  1. "asthenia"
Formats
  1. Journal Article (251)
  2. Review (7)
  3. Conference Paper (1)
  4. Research Letter (1)
Groups
  1. Department of Medicine (207)
  2. Solid Tumor Oncology Division (174)
  3. Genitourinary Oncology Service (58)
  4. Breast Medicine Service (37)
  5. Hematologic Malignancies, Division of (34)
  6. Gastrointestinal Oncology Service (31)

More Groups

People
  1. Robert Motzer (38)
  2. Jose Baselga (13)
  3. Andrew Seidman (10)
  4. Clifford Hudis (9)
  5. David Ilson (9)
  6. Eileen O'Reilly (9)

More People

Years
  1. 2025 (8)
  2. 2024 (19)
  3. 2023 (13)
  4. 2022 (8)
  5. 2021 (12)
  6. 2020 (14)

More Years

Publications
  1. Journal of Clinical Oncology (24)
  2. Lancet Oncology (24)
  3. Annals of Oncology (15)
  4. Clinical Cancer Research (13)
  5. European Journal of Cancer (9)
  6. New England Journal of Medicine (9)

More Publications

Publishers
  1. Elsevier Inc. (42)
  2. Elsevier Science, Inc. (39)
  3. American Society of Clinical Oncology (26)
  4. Oxford University Press (25)
  5. Nature Publishing Group (17)
  6. Springer (15)

More Publishers

Results (260)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): An interim analysis of the multicentre, double-blind, randomised phase 3 study
    Journal Article

    Shitara, K.; Rha, S. Y.; Wyrwicz, L. S.; Oshima, T.; Karaseva, N.; Osipov, M.; Yasui, H.; Yabusaki, H.; Afanasyev, S.; Park, Y. K.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Interferons in the treatment of myeloproliferative neoplasms
    Review

    Vachhani, P.; Mascarenhas, J.; Bose, P.; Hobbs, G.; Yacoub, A.; Palmer, J. M.; Gerds, A. T.; Masarova, L.; Kuykendall, A. T.; Rampal, R. K.; more...
    Therapeutic Advances in Hematology (2024)

    Fulltext@MSK | Save
  • Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
    Journal Article

    Patel, S. P.; Alonso-Gordoa, T.; Banerjee, S.; Wang, D.; Naidoo, J.; Standifer, N. E.; Palmer, D. C.; Cheng, L. Y.; Kourtesis, P.; Ascierto, M. L.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
    Journal Article

    Brahmer, J. R.; Long, G. V.; Hamid, O.; Garon, E. B.; Herbst, R. S.; Andre, T.; Armand, P.; Bajorin, D.; Bellmunt, J.; Burtness, B.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors
    Journal Article

    Lewis, K. D.; Peris, K.; Sekulic, A.; Stratigos, A. J.; Dunn, L.; Eroglu, Z.; Chang, A. L. S.; Migden, M. R.; Yoo, S. Y.; Mohan, K.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of LY3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors
    Journal Article

    Garralda, E.; Schram, A. M.; Bedard, P. L.; Schwartz, G. K.; Yuen, E.; McNeely, S. C.; Ribeiro, S.; Cunningham, J.; Wang, Y.; Urunuela, A.; more...
    The Oncologist (2024)

    Fulltext@MSK | Save
  • First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
    Journal Article

    Janku, F.; Kim, T. M.; Iyer, G.; Spreafico, A.; Elez, E.; de Jonge, M.; Yamamoto, N.; van der Wekken, A. J.; Ascierto, P. A.; Maur, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
    Journal Article

    Le, X.; Paz-Ares, L. G.; Van Meerbeeck, J.; Viteri, S.; Galvez, C. C.; Smit, E. F.; Garassino, M.; Veillon, R.; Baz, D. V.; Pradera, J. F.; more...
    Cell Reports Medicine (2023)

    Fulltext@MSK | Save
  • Phase Ib/II study of the efficacy and safety of binimetinib (MEK162) plus panitumumab for mutant or wild-type RAS metastatic colorectal cancer
    Journal Article

    Van Cutsem, E.; Yaeger, R.; Delord, J. P.; Tabernero, J.; Siu, L. L.; Ducreux, M.; Siena, S.; Elez, E.; Kasper, S.; Zander, T.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial
    Journal Article

    Wainberg, Z. A.; Melisi, D.; Macarulla, T.; Pazo Cid, R.; Chandana, S. R.; De La Fouchardière, C.; Dean, A.; Kiss, I.; Lee, W. J.; Goetze, T. O.; more...
    Lancet (2023)

    Fulltext@MSK | Save